2-Methoxyestradiol: A potential treatment for multiple proliferative disorders

Endocrinology

Volumn 148, Issue 9, 2007, Pages 4125-4127

  Dubey, Raghvendra K ^a,b   Imthurn, Bruno ^a   Jackson, Edwin K ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ESTRADIOL; ESTROGEN;

ATHEROSCLEROSIS; BINDING SITE; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE COURSE; ESTROGEN THERAPY; HUMAN; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; NONHUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; SHORT SURVEY;

CARDIOVASCULAR DISEASES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MUSCLE, SMOOTH, VASCULAR; TUBULIN MODULATORS;

EID: 34548096433     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2007-0514     Document Type: Short Survey

References (21)

1. Dubey RK, Jackson EK 2001 Invited review: estrogen-induced cardiorenal protection: potential cellular, biochemical, and molecular mechanisms. Am J Physiol Renal Physiol 280:F365-F388
2. Dubey RK, Jackson EK 2001 Invited review: cardiovascular protective effects of 17β-estradiol metabolites. J Appl Physiol 91:1868-1883
3. Dubey RK, Imthurn B, Barton M, Jackson EK 2005 Vascular consequences of menopause and hormone therapy: Importance of timing of treatment and type of estrogen. Cardiovasc Res 66:295-306
4. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E 1998 Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 280: 605-613
5. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
6. Barchiesi F, Jackson EK, Imthurn B, Fingerle J, Gillespie DG, Dubey RK 2004 Differential regulation of estrogen receptor subtypes α and β in human aortic smooth muscle cells by oligonucleotides and estradiol. J Clin Endocrinol Metab 89:2373-2381
7. Dubey RK, Gillespie DG, Zacharia LC, Rosselli M, Korzekwa KR, Fingerle J, Jackson EK 2000 Methoxyestradiols mediate the antimitogenic effects of estradiol on vascular smooth muscle cells via estrogen receptor-independent mechanisms. Biochem Biophys Res Commun 278:27-33
8. Barchiesi F, Jackson EK, Gillespie DG, Zacharia LC, Fingerle J, Dubey RK 2002 Methoxyestradiols mediate estradiol-induced antimitogenesis in human aortic SMCs. Hypertension 39:874-879
9. Barchiesi F, Jackson EK, Fingerle J, Gillespie DG, Odermatt B, Dubey RK 2006 2-Methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle. Circ Res 99:266-274
10. Mooberry SL 2003 New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Curr Opin Oncol 15:425-430
11. Sweeney C, Liu G, Yiannoutsos C, Kolesar J, Horvath D, Staab MJ, Fife K, Armstrong V, Treston A, Sidor C, Wilding G 2005 Phase II multicenter, randomized, double blinded, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormonerefractory prostate cancer. Clin Can Res 11:6625-6633
12. Bourghardt J, Bergström G, Krettek A, Sjöberg S, Borèn J, Tivesten A 2007 The endogenous estradiol metabolite 2-methoxyestradiol reduces atherosclerotic lesion formation in female apoE-deficient mice. Endocrinology 148:4128-4132
13. Dawling S, Roodi N, Parl FF 2003 Methoxyestrogens exert feedback inhibition on cytochrome P450 1A1 and 1B. Cancer Res 63:3127-3132
14. Sibonga JD, Lotinun S, Evans GL, Pribluda VS, Green SJ, Turner RT 2003 Dose response effects of 2-methoxyestradiol on estrogen target tissues in the ovariectomized rat. Endocrinology 144:785-792
15. Tofovic S, Dubey RK, Jackson EK 2001 2-Hydroxyestradiol attenuates the development of obesity, the metabolic syndrome, and vascular and renal dysfunction in obese ZSF1 rats. J Pharmacol Exp Ther 299:973-977
16. Tofovic SP, Dubey RK, Salah EM, Jackson EK 2002 2-Hydroxyestradiol attenuates renal disease in chronic puromycin aminonucleoside nephropathy. J Am Soc Nephrol 13:2737-2747
17. Tofovic SP, Salah EM, Dubey RK, Melhem MF, Jackson EK 2005 Estradiol metabolites attenuate renal and cardiovascular injury induced by chronic nitric oxide synthase inhibition. J Cardiovasc Pharmacol 46:25-35
18. Tofovic SP, Salah EM, Mady HH, Jackson EK, Melhem MF 2005 Estradiol metabolites attenuate monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol 46:430-437
19. Zacharia LC, Gogos JA, Karayiorgou M, Jackson EK, Gillespie DG, Barchiesi F, Dubey RK 2003 Methoxyestradiols mediate the antimitogenic effects of 17β-estradiol. Direct evidence from catechol-O- methyltransferase-knockout mice. Circulation 108:2974-2978
20. Karas RH, Schulten H, Pare G, Aronovitz MJ, Ohlsson C, Gustafsson JA, Mendelsohn ME 2001 Effects of estrogen on the vascular injury response in estrogen receptor α,β (double knockout) mice. Circ Res 89:534-539
21. Takahashi M, Shimomoto T, Miyajima K, Yoshida M, Katashima S, Uematsu F, Maekawa A, Nakae D 2004 Effects of estrogens and metabolites on endometrial carcinogenesis in young adult mice initiated with N-ethyl-N′-nitro-N-nitrosoguanidine. Cancer Lett 211:1-9